When “Fibrotic” Does Not Mean Progressive: Interpreting a Trial of Nintedanib in Post-COVID-19 Lung Disease

Mark G Jones; When “Fibrotic” Does Not Mean Progressive: Interpreting a Trial of Nintedanib in Post-COVID-19 Lung Disease, Annals of the American Thoracic

Authors

Institutions

Publication Details

Journal
Annals of the American Thoracic Society
Published
2026-07-16
DOI
https://doi.org/10.1093/annalsats/aaoag201
Primary Topic
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

When “Fibrotic” Does Not Mean Progressive: Interpreting a Trial of Nintedanib in Post-COVID-19 Lung Disease

Mark G Jones
Annals of the American Thoracic Society
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
article

When “Fibrotic” Does Not Mean Progressive: Interpreting a Trial of Nintedanib in Post-COVID-19 Lung Disease

Mark G Jones
article en

Abstract

Mark G Jones; When “Fibrotic” Does Not Mean Progressive: Interpreting a Trial of Nintedanib in Post-COVID-19 Lung Disease, Annals of the American Thoracic

Annals of the American Thoracic Society
NIHR Southampton Respiratory Biomedical Research Unit (GB)
Openalex Percentile: Top 9%
Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.